The overall infection rate stood at 15.59 percent and 89.39 percent – have recovered so far, the Directorate General of Health Services said.
The country’s infection number reached the 500,000-mark on December 20. The first cases were reported on March 8. The death toll exceeded 7,000 on December 12.
Covid-19 across the globe
The COVID-19 pandemic continues to devastate countries across the world, as cases approach 89 million..
According to the latest data released by Johns Hopkins University, the total count of COVID cases reached 88, 821,629, while the death toll mounted to 1,911,637 on Saturday morning.
In the US, the worst-hit country of the world, the infection tally topped near 21 million (21,857,293) while the death toll climbed to 368,736, the figures revealed.
The seven-day average positivity rate for the nation has continued to rise since Christmas, and stood at 13.6 percent on Thursday, according to the COVID Tracking Project. That’s well above the 10 percent rate considered a marker of widespread contagion, reports AP.
Brazil recorded over 8 million COVID-19 cases on Friday, a day after reaching the grim milestone of 200,000 deaths from the disease.
India remains the second worst-hit country in the world in terms of cases.
Progress of vaccine
The government on Thursday approved the emergency use of the Oxford-AstraZeneca Covid-19 vaccine.
The approval will allow Beximco Pharmaceuticals to bring doses from the Serum Institute of India, which is manufacturing the vaccine, Mohammad Salahuddin, deputy director of the Directorate General of Drug Administration, said.
On December 13, the government signed an agreement with Serum Institute for procuring Oxford-AstraZeneca Covid-19 vaccine.
Under the deal, Bangladesh will import 3 crore doses of SARS-Cov-2 AZD 1222 (Oxford-Astrazeneca vaccine) from Serum in the next six months.
“If everything goes well, then we’ll get the vaccines in mid-January,” Health Minister Zahid Maleques said.
The process to bring Oxford-Astrazeneca vaccine would start in January next, said Zahid adding that a decision was taken in principle that Serum Institute would provide the vaccine at the same price they would procure.
On December 28, Bangladeshi pharmaceutical company Globe Biotech got approval from the DGDA for manufacturing Covid-19 vaccine for clinical trials.
Dr Mohammad Mohiuddin, Manager of Globe Biotech Limited (Head of Quality Operation), said after completing the trial, Globe Biotech would start supplying vaccines following the protocol.
“Hopefully, we’ll be able to begin clinical trials in January. It’ll take five months to finish,” he said. “Vaccine will be available by June if we can begin the clinical trial this month.